These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 27216947)

  • 1. Clinical Effectiveness of Liraglutide vs Sitagliptin on Glycemic Control and Body Weight in Patients with Type 2 Diabetes: A Retrospective Assessment in Sweden.
    Lind M; Matsson PO; Linder R; Svenningsson I; Jørgensen L; Ploug UJ; Gydesen H; Dorkhan M; Larsen S; Johansson G
    Diabetes Ther; 2016 Jun; 7(2):321-33. PubMed ID: 27216947
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-World Clinical Effectiveness and Cost Savings of Liraglutide Versus Sitagliptin in Treating Type 2 Diabetes for 1 and 2 Years.
    Li Q; Ganguly R; Ganz ML; Gamble C; Dang-Tan T
    Diabetes Ther; 2018 Jun; 9(3):1279-1293. PubMed ID: 29744818
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-world Effectiveness of Liraglutide vs. Sitagliptin Among Older Patients with Type 2 Diabetes Enrolled in a Medicare Advantage Prescription Drug Plan: A Retrospective Observational Study.
    Dang-Tan T; Kamble PS; Meah Y; Gamble C; Ganguly R; Horter L
    Diabetes Ther; 2020 Jan; 11(1):213-228. PubMed ID: 31820328
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-Term Effectiveness of Liraglutide for Treatment of Type 2 Diabetes in a Real-Life Setting: A 24-Month, Multicenter, Non-interventional, Retrospective Study.
    Lapolla A; Berra C; Boemi M; Bossi AC; Candido R; Di Cianni G; Frontoni S; Genovese S; Ponzani P; Provenzano V; Russo GT; Sciangula L; Simioni N; Bette C; Nicolucci A;
    Adv Ther; 2018 Feb; 35(2):243-253. PubMed ID: 29270781
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Retrospective Database Study of Liraglutide Persistence Associated with Glycemic and Body Weight Control in Patients with Type 2 Diabetes.
    Melzer-Cohen C; Chodick G; Husemoen LLN; Rhee N; Shalev V; Karasik A
    Diabetes Ther; 2019 Apr; 10(2):683-696. PubMed ID: 30815829
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness and Persistence of Liraglutide Treatment Among Patients with Type 2 Diabetes Treated in Primary Care and Specialist Settings: A Subgroup Analysis from the EVIDENCE Study, a Prospective, 2-Year Follow-up, Observational, Post-Marketing Study.
    Martinez L; Penfornis A; Gautier JF; Eschwège E; Charpentier G; Bouzidi A; Gourdy P
    Adv Ther; 2017 Mar; 34(3):674-685. PubMed ID: 28138803
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-world clinical and economic outcomes of liraglutide versus sitagliptin in patients with type 2 diabetes mellitus in the United States.
    Li Q; Chitnis A; Hammer M; Langer J
    Diabetes Ther; 2014 Dec; 5(2):579-90. PubMed ID: 25256818
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of Liraglutide and Lixisenatide in the Treatment of Type 2 Diabetes: Real-World Evidence from The Health Improvement Network (THIN) Database in the United Kingdom.
    Feher M; Vega-Hernandez G; Mocevic E; Buysse B; Myland M; Power GS; Nystrup Husemoen LL; Kim J; Witte DR
    Diabetes Ther; 2017 Apr; 8(2):417-431. PubMed ID: 28281244
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Effectiveness of Liraglutide in Type 2 Diabetes Treatment in the Real-World Setting: A Systematic Literature Review.
    Ostawal A; Mocevic E; Kragh N; Xu W
    Diabetes Ther; 2016 Sep; 7(3):411-38. PubMed ID: 27350545
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Switching from sitagliptin to liraglutide to manage patients with type 2 diabetes in the UK: A long-term cost-effectiveness analysis.
    Barnett AH; Arnoldini S; Hunt B; Subramanian G; Hoxer CS
    Diabetes Obes Metab; 2018 Aug; 20(8):1921-1927. PubMed ID: 29652101
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial.
    Pieber TR; Bode B; Mertens A; Cho YM; Christiansen E; Hertz CL; Wallenstein SOR; Buse JB;
    Lancet Diabetes Endocrinol; 2019 Jul; 7(7):528-539. PubMed ID: 31189520
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative Efficacy of Adding Sitagliptin to Metformin, Sulfonylurea or Dual Therapy: A Propensity Score-Weighted Cohort Study.
    Mamza J; Mehta R; Donnelly R; Idris I
    Diabetes Ther; 2015 Jun; 6(2):213-26. PubMed ID: 26014844
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral Semaglutide Versus Empagliflozin, Sitagliptin and Liraglutide in the UK: Long-Term Cost-Effectiveness Analyses Based on the PIONEER Clinical Trial Programme.
    Bain SC; Hansen BB; Malkin SJP; Nuhoho S; Valentine WJ; Chubb B; Hunt B; Capehorn M
    Diabetes Ther; 2020 Jan; 11(1):259-277. PubMed ID: 31833042
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial.
    Pratley RE; Nauck M; Bailey T; Montanya E; Cuddihy R; Filetti S; Thomsen AB; Søndergaard RE; Davies M;
    Lancet; 2010 Apr; 375(9724):1447-56. PubMed ID: 20417856
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-Effectiveness Analysis of Incretin Therapy for Type 2 Diabetes in Spain: 1.8 mg Liraglutide Versus Sitagliptin.
    Pérez A; Mezquita Raya P; Ramírez de Arellano A; Briones T; Hunt B; Valentine WJ
    Diabetes Ther; 2015 Mar; 6(1):61-74. PubMed ID: 25742705
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial.
    Pratley R; Amod A; Hoff ST; Kadowaki T; Lingvay I; Nauck M; Pedersen KB; Saugstrup T; Meier JJ;
    Lancet; 2019 Jul; 394(10192):39-50. PubMed ID: 31186120
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Liraglutide Effect on Weight, Glycated Hemoglobin, and Blood Pressure: A Single-Center Experience in the Eastern Province of Saudi Arabia.
    Alsafwani DM; Alotaibi HN; Alzaid JA; Alghamdi A; Almakhaita HM
    Cureus; 2022 Mar; 14(3):e23554. PubMed ID: 35371841
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term clinical and economic outcomes associated with liraglutide versus sitagliptin therapy when added to metformin in the treatment of type 2 diabetes: a CORE Diabetes Model analysis.
    Lee WC; Samyshkin Y; Langer J; Palmer JL
    J Med Econ; 2012; 15 Suppl 2():28-37. PubMed ID: 22834986
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-benefit comparison of liraglutide and sitagliptin in the treatment of type 2 diabetes in Thailand.
    Deerochanawong C; Kosachunhanun N; Gadekar AV; Chotikanokrat P; Permsuwan U
    Clinicoecon Outcomes Res; 2019; 11():423-430. PubMed ID: 31372015
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term efficacy of liraglutide in Indian patients with Type 2 diabetes in a real-world setting.
    Kaur P; Mahendru S; Mithal A
    Indian J Endocrinol Metab; 2016; 20(5):595-599. PubMed ID: 27730066
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.